Results 81 to 90 of about 11,256 (207)

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, Volume 159, Issue 9, Page 2290-2299, 1 November 2026.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Protein Lactylation in Cancer: From Mechanisms to Therapy

MedComm, Volume 7, Issue 11, November 2026.
Increased glycolysis and lactate accumulation promote histone and nonhistone protein lactylation, linking tumor metabolic reprogramming to treatment adaptation. Lactylation enhances DNA repair, suppresses antitumor immunity, strengthens antioxidant defenses, and facilitates cell‐cycle checkpoint escape, collectively promoting resistance to chemotherapy,
Wentian Huang, Ping Hu, Shun Wang, Xide Zhang, Ziran Ye, Shengqiang Chen, Fu Gao, Yuanyuan Chen, Yanyong Yang   +8 more
wiley   +1 more source

Nitroalkenes exploit dependence on autophagy-lysosome pathway in PARPi-Resistant triple negative breast cancer

\ua9 2026 The Authors.Lack of DNA double-strand break repair efficiency exquisitely sensitizes cancers to poly-ADP ribose polymerase inhibitors (PARPi). Unfortunately, resistance to PARPi poses an insurmountable challenge for patients.
Hong L, Lee S, Schopfer FJ, Lee AV, Kataura T, Frisbie L, Coffman LG, Zhao Y, Merkel C, Freeman BA, Skoko JJ, Korolchuk VI, Neumann CA   +12 more
core   +2 more sources

AI‐Based Analysis of Tumor‐Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025‐A1 Study

Cancer Science, Volume 117, Issue 11, Page 3160-3170, November 2026.
AI‐based spatial analysis of tumor‐infiltrating lymphocytes in ovarian cancer revealed the highest infiltration in high‐grade serous carcinoma. Integrating pathology‐based immune phenotypes with HRD status provided additional prognostic insight and highlighted distinct relationships between TILs and genomic structure.
Kohei Hamada, Junzo Hamanishi, Noriomi Matsumura, Akihiko Ueda, Shiro Takamatsu, Kosuke Yoshihara, Takayuki Nagasawa, Toshiyuki Seki, Akira Kikuchi, Etsuko Fujimoto, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Hisaaki Kudo, Katsutoshi Oda, Muneaki Shimada, Aikou Okamoto, Masaki Mandai   +17 more
wiley   +1 more source

HRD effects on first-line adjuvant chemotherapy and PARPi maintenance therapy in Chinese ovarian cancer patients

, 2023
Homologous recombination deficiency (HRD) testing has been approved by FDA for selecting epithelial ovarian cancer (EOC) patients who may benefit from the first-line poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy. However, the effects
Zhu, Xiaoru, Xinyun Xu, Li-juan Wang, Han Liang, Dong, Yu, Ji, Xuwo, Lv, Ran, Chao Xue, Gu, Yu, Yang Zhang, Zhang, Mengpei, Jiao, Kai, Rutie Yin, Yin, Rutie, Liang, Han, Wu, Ming, Yu Dong, Ran Lv, Kai Jiao, Ying Jin, Sun, Tianqi, Jin, Ying, Xu, Xinyun, Xuwo Ji, Lei Li, Ming Wu, Li, Zhe, Wang, Li-Juan, Shi, Xiaohua, Yu Gu, Mengpei Zhang, Xiaohua Shi, Zhiyong Liang, Zhang, Yang, Liang, Zhiyong, Xue, Chao, Tianqi Sun, Xiaoru Zhu, Zhe Li, Li, Lei   +39 more
core   +1 more source

Combining PARPi-FL fluorescence and reflectance contrast for improved detection of basal cell carcinoma (BCC)

, 2021
Towa rds improving non-invasive BCC diagnosis, we demonstrate successful PARPi-FL (PARP1-ta rgeted nuclear contrast) la beling in tumors, permeability through stratum corneum, and high dia gnostic accuracy with combined PARPi-FL a nd reflectance ...
Wu X., Sahu A., Cordero J., Lee E., Monnier J., Kumar P., Rossi A., Dusza S., Rajadhyaksha M., Fox C., Franca P. D. D., Kossatz S., Everett N., Reiner T., Pulitzer M., Kurtansky N., Halpern A., Jain M., Harris U., Kose K., Roberts S., Brand C., Nehal K., Phillips W., Chen C. -S. J., Longo C.   +25 more
core  

Gasdermin C sensitizes tumor cells to PARP inhibitor therapy in cancer models

The Journal of Clinical Investigation
Several poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are approved by FDA to treat cancer with BRCA mutations. BRCA mutations are considered to fuel a PARPi killing effect by inducing apoptosis.
Shuanglian Wang, Chiung-Wen Chang, Juan Huang, Shan Zeng, Xin Zhang, Mien-Chie Hung, Junwei Hou   +6 more
doaj   +1 more source

Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition

Cell Death Discovery
PARP inhibitors (PARPi) are approved for the treatment of platinum-based therapy-responsive ovarian cancer. However, this severely restricts their therapeutic potential, since there is only limited knowledge on the efficacy of PARPi in platinum drug ...
Philipp König, Leon Bade, Julia Maria Eichhorn, Helena Skalski, Jindrich Cinatl, Martin Michaelis, Gerd Bendas   +6 more
doaj   +1 more source

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors

Molecules, 2019
Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR).
Benjamin D. Dickson, Way Wua Wong, William R. Wilson, Michael P. Hay   +3 more
doaj   +1 more source

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer

Advanced Science
Most clinical PARP inhibitors (PARPis) trap PARP1 in a chromatin‐bound state, leading to PARPi‐mediated cytotoxicity. PARPi resistance impedes the treatment of ovarian cancer in clinical practice.
Zhiyan Zhan, Jiarong Zhang, Huisheng Liang, Chong Wang, Li Hong, Wenxue Liu   +5 more
doaj   +1 more source